Ivermectin and COVID-19 in Care Home: Case Report
Loué Pierre, Fardeau Christine
Journal of Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202
Check for updates droxychloroquine and azithromycin. Ivermectin (IVM) was suggested empirically as known for in vivo anti dengue Flavivirus [5] and in vitro antiviral activity against HIV [6] dengue [7, 8] and chikungunya [8] . In care home IVM is an option for treatment of scabies, including for community infection control [9] . In the other hand IVM is worldwide used for the treatment of river blindness caused by onchocerciasis infection [10] . Side effects including mainly allergic rash and decrease in tension, were declared at a very low rate [9, 10] . Of the 25 PCR-positive patients, 10 chose to take the IVM treatment (group 1) and 15 chose not to take IVM (group 2). Patients of the group 1 received a single dose of 200 micrograms/kg body weight. Individual daily medical check was scheduled for the 2 months of the lockdown period that lasted from April 3 to May 15, 2020 for all patients. The monitoring protocol, imple-
References
Bernigaud, Guillemot, Ahmed-Belkacem, Grimaldi-Bensouda, Lespine, Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality, Br J Dermatol
Boussinesq, Chipaux, Ernould, Prod'hon, Quillévéré, Efficacité parasitologique de traite
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Chaccour, Ruiz-Castillo, Richardson, Moncunill, Casellas, The SARS-CoV-2 ivermectin navarra-isglobal trial (SAINT) to evaluate the potential of ivermectin to reduce COVID-19 transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial, Trials
Changeux, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, C R Biol
Changeux, The nicotinic acetylcholine receptor: A typical 'allosteric machine, Philos Trans R Soc Lond B Biol Sci
Guerrero, Bravo, Muñoz, Grillo, Guerrero, COVID-19: The ivermectin African enigma, Colomb Med
Insee, Évolution du nombre de décès entre le premier mars et le 30 avril
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol
Momekov, Momekova, Ivermectin as a potential Covid-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens, MedRxiv,
doi:10.1101/2020.04.11.20061804v2Romani, Marks, Sokana, Nasi, Kamoriki, Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: A single-arm community intervention trial, Lancet Infect Dis
Santos, Natural history of COVID-19 and current knowledge on treatment therapeutic options, Biomed Pharmacother
Susen, Tacquard, Godon, Mansour, Garrigue, Traitements anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec covid-19 et surveillance de l'hémostase
Tay, Fraser, Chan, Moreland, Rathore, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir Res
Varghese, Kaukinen, Glaesker, Bespalov, Hanski, Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir Res
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Yamasmith, Saleh-Arong Fa-H, Avirutnan, Angkasekwinai, Mairiang, Efficacy and safety of ivermectin against dengue infection: A phase III, randomized, double-blind, placebo-controlled trial
Yan, Ci, Chen, Chen, Li, Anti-inflammatory effect of ivermectin in mouse model of allergic asthma, Inflamm Res
Yang, Atkinson, Wang, Lee, Bogoyevitch, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res
DOI record:
{
"DOI": "10.23937/2474-3658/1510202",
"ISSN": [
"2474-3658"
],
"URL": "http://dx.doi.org/10.23937/2474-3658/1510202",
"author": [
{
"affiliation": [],
"family": "Pierre",
"given": "Loué",
"sequence": "first"
},
{
"affiliation": [],
"family": "Christine",
"given": "Fardeau",
"sequence": "additional"
}
],
"container-title": "Journal of Infectious Diseases and Epidemiology",
"container-title-short": "J Infect Dis Epidemiol",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinmedjournals.org"
]
},
"created": {
"date-parts": [
[
2021,
4,
22
]
],
"date-time": "2021-04-22T12:42:39Z",
"timestamp": 1619095359000
},
"deposited": {
"date-parts": [
[
2021,
4,
22
]
],
"date-time": "2021-04-22T12:42:41Z",
"timestamp": 1619095361000
},
"indexed": {
"date-parts": [
[
2022,
3,
29
]
],
"date-time": "2022-03-29T23:35:42Z",
"timestamp": 1648596942379
},
"is-referenced-by-count": 0,
"issue": "4",
"issued": {
"date-parts": [
[
2021,
4,
30
]
]
},
"journal-issue": {
"issue": "4",
"published-online": {
"date-parts": [
[
2021,
4,
30
]
]
}
},
"member": "10022",
"original-title": [],
"prefix": "10.23937",
"published": {
"date-parts": [
[
2021,
4,
30
]
]
},
"published-online": {
"date-parts": [
[
2021,
4,
30
]
]
},
"publisher": "ClinMed International Library",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.clinmedjournals.org/articles/jide/journal-of-infectious-diseases-and-epidemiology-jide-7-202.php?jid=jide"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Medicine"
],
"subtitle": [],
"title": "Ivermectin and COVID-19 in Care Home: Case Report",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.23937/clinmed-crossmark-policy",
"volume": "7"
}
